Inovio Pharmaceuticals, Inc. Forecast, price target & analysts
Inovio Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Inovio Pharmaceuticals, Inc. Classifications & Recommendation:
Inovio Pharmaceuticals, Inc. Price Target
| Target Price | $7.83 |
| Price | $1.89 |
| Potential |
314.46%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Inovio Pharmaceuticals, Inc. 2026 .
The average Inovio Pharmaceuticals, Inc. target price is $7.83.
This is
314.46%
register free of charge
$15.00
693.65%
register free of charge
$2.00
5.82%
register free of charge
|
|
| A rating was issued by 6 analysts: 3 Analysts recommend Inovio Pharmaceuticals, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Inovio Pharmaceuticals, Inc. stock has an average upside potential 2026 of
314.46%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.22 | 2.57 |
| 73.49% | 1,066.00% | |
| Net Margin | -64,815.91% | -1,351.02% |
| 144.70% | 97.92% |
6 Analysts have issued a sales forecast Inovio Pharmaceuticals, Inc. 2025 . The average Inovio Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued a net profit forecast Inovio Pharmaceuticals, Inc. 2025 . The average Inovio Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.95 | -0.96 |
| 35.14% | 75.70% | |
| P/E | negative | |
| EV/Sales | negative |
1 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast for earnings per share. The average Inovio Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Inovio Pharmaceuticals, Inc....
Current Inovio Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 18 2024 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Nov 18 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
